Profil Penggunaan Obat Antivirus Covid-19 Di Rsud Dr. Murjani-Sampit

Suryanti, Etik and Rahem, Abdul and Purnamayanti, Anita (2022) Profil Penggunaan Obat Antivirus Covid-19 Di Rsud Dr. Murjani-Sampit. Jurnal Ilmiah Ibnu Sina, 7 (1). (Submitted)

[thumbnail of Penerimaan Artikel Untuk Dipublikasikan Etik Suryanti.pdf] PDF
Penerimaan Artikel Untuk Dipublikasikan Etik Suryanti.pdf

Download (125kB)
Restricted to Registered users only

Download (155kB) | Request a copy


Coronavirus Disease 2019 (Covid-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2). The World Health Organization (WHO) until now still defines Covid-19 as a global pandemic where this pandemic is the cause of the biggest publ ic health crisis in this century. RSUD dr. Murjani-Sampit uses several antivirals, including Oseltamivir 75 mg, Favipiravir 200 mg, Remdesivir 200 mg. The purpose of th is study was to determine the antiviral profile given to covid-19 patients at dr. Murjani-Sampit. This study used a total sample of hospitalized patients who were given COVID-19 antiviral therapy in the period August 2021. This research method used an observational research design with retrospective sampli ng. Data collection techniques based on observ ation of patient prescrip tion data recorded in the pharmacy installation management information system of RSUD dr. Murjani-Sampit. The analytical method used is descriptive analysis with the most data on the use of antiviral drugs and the a verage percentage for th e period August 2021 at dr. Murjani-Sampit which opened 275 patients. The results showed that the most widely administered antivirals were favipiravir 200 mg in 249 patients (90.54% ), remdesivir 200 mg in 17 patients (6.18%) and oseltamivir as adjuvant or addi tional therapy due to influenza in 9 patients (3.27%). The conclusion of this st udy is that the antivirals used include oseltamivir 75 mg 3.27%, favipiravir 200 mg 90.54%, and remdesivir 200 mg 6.18%

Item Type: Article
Uncontrolled Keywords: ovid-19, antiviral, percentage
Subjects: R Medicine > R Medicine (General)
R Medicine > RS Pharmacy and materia medica
Divisions: Postgraduate Programs > Master Program in Clinical Pharmacy
Depositing User: ETIK SURYANTI
Date Deposited: 03 Feb 2022 04:52
Last Modified: 09 Feb 2022 05:00

Actions (login required)

View Item View Item